[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) reported an insider equity transaction by its Chief Operating Officer. On 11/13/2025, the officer acquired 48,900 shares of common stock at $0, reflecting the vesting of performance-based restricted stock units after a development milestone was achieved. On 11/14/2025, 6,902 shares were sold at $11.1769 in a sell-to-cover transaction for taxes tied to this vesting. Following these transactions, the officer directly beneficially owned 105,373 shares of Kura Oncology common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FORD KATHLEEN

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		A		48,900	A	$0	112,275	D
Common Stock	11/14/2025		S(1)		6,902	D	$11.1769	105,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

	Teresa Bair, Attorney-in-fact for Kathleen Ford	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report in this Form 4?

The Chief Operating Officer reported the vesting of performance-based restricted stock units resulting in the acquisition of 48,900 shares of common stock on 11/13/2025, followed by a sale of 6,902 shares on 11/14/2025 to cover taxes.

How many Kura Oncology (KURA) shares does the reporting person own after the transactions?

After the reported acquisition and tax-related sale, the Chief Operating Officer directly beneficially owned 105,373 shares of Kura Oncology common stock.

What triggered the vesting of Kura Oncology performance-based RSUs in this filing?

The vesting occurred because the performance criteria for one specified development milestone were determined to be met on November 13, 2025, causing 1/6th of the underlying performance-based restricted stock units granted on May 31, 2023 to vest.

Why were 6,902 Kura Oncology (KURA) shares sold by the reporting person?

The 6,902 shares were sold as a sell-to-cover for taxes associated with the vesting of the performance-based restricted stock units, as explained in the filing.

What type of equity award is involved in this Kura Oncology insider transaction?

The transaction involves performance-based restricted stock units (PSUs), where each PSU represents the contingent right to receive one share of Kura Oncology common stock upon achieving specified development milestones and related vesting dates.

What role does the reporting person hold at Kura Oncology (KURA)?

The reporting person is an officer of Kura Oncology, serving as the company’s Chief Operating Officer.